Amylyx Pharmaceuticals stock drops 80% after ALS drug fails late-stage trial
Amylyx Pharmaceuticals shares dropped more than 80% early Friday after the company said its ALS treatment Relyvrio failed a late-stage trial and may be pulled from the market.